MoonLake Immunotherapeutics Announces Favorable Phase 3 Trial Outcomes for Sonelokimab in HS Treatment

MoonLake Immunotherapeutics has reported positive one-year results from its Phase 3 trials for sonelokimab in treating moderate-to-severe hidradenitis suppurativa. The data showed a strong therapeutic response and no new safety concerns. The company plans to submit a Biologics License Application for the drug later this year.